Fluticasone Nasal Spray Label Centers on Local Injury, Ocular Risk, and Systemic Steroid Exposure
The updated prescribing information for fluticasone propionate nasal spray keeps the drug’s role narrow and familiar: relief of the nasal symptoms of perennial nonallergic rhinitis in adults and children aged 4 years and older. The label also makes clear that this is an intranasal corticosteroid with a safety profile that depends on local delivery, regular use, and careful attention to patients who may be more vulnerable to steroid toxicity. Initial U.S. approval dates to 1994, while the most recent major change flagged in the label concerns glaucoma and cataracts.
The practical message in the label is not subtle. Even a medication designed for the nose can create problems well beyond the nasal cavity when dosing is excessive, when it is paired with strong metabolic inhibitors, or when susceptible patients are exposed for long periods.
Dosing Is Simple, But Adherence and Technique Drive the Response
The product is intended for intranasal use only. Before first use, or after at least one week without the spray, the bottle should be primed by shaking well and releasing six sprays into the air away from the face. The label also instructs patients to shake gently before each use, a small but important step for consistent dosing from a metered device.
Adults start at 2 sprays per nostril once daily for a total daily dose of 200 mcg. The same total dose can also be delivered as 1 spray per nostril twice daily, and after the first few days some patients may be able to step down to 1 spray in each nostril once daily for maintenance. Children and adolescents aged 4 years and older begin at 1 spray per nostril once daily, for a total of 100 mcg per day.
Regular use matters because the full effect may take several days, and symptom relief is not immediate or uniform across patients. In other words, this is a controller therapy rather than a rescue medication. The label’s dose ceiling is equally direct: patients should not exceed 2 sprays in each nostril per day, for a total of 200 mcg.
Nasal Mucosa Takes the First Hit
Local adverse effects dominate the warning section. Epistaxis, nasal ulceration, Candida albicans infection, nasal septal perforation, and impaired wound healing are all identified risks. Monitoring for nasal mucosal injury is recommended, and use should be avoided in patients with recent nasal ulcers, nasal surgery, or nasal trauma.
That warning reflects the biology of topical corticosteroids. By suppressing inflammation, the drug can ease rhinitis symptoms, but the same anti-inflammatory effect can thin or destabilize fragile mucosa in some patients. The nose is the first site of exposure, so it is also the first place where chronic irritation, bleeding, or ulceration may appear.
Bleeding from the nose is not a trivial side effect when it persists.
Eye Complications Enter the Label for Long-Term Users
The label also flags glaucoma and cataracts, with a recommendation to consider ophthalmology referral in patients who develop ocular symptoms or who use fluticasone long term. The concern is familiar across corticosteroid therapy: steroid exposure can affect intraocular pressure and lens clarity over time, especially in patients who remain on treatment chronically.
This warning gives clinicians a reason to ask about visual symptoms rather than treating the spray as a purely local therapy with no downstream consequences. Patients with persistent blurred vision, eye pain, halos, or other ocular complaints should not be managed as if the issue is unrelated to the nasal spray simply because the drug is administered intranasally.
Hypersensitivity and Infection Risks Require Early Stop Rules
Post-administration hypersensitivity reactions have been reported, including anaphylaxis, angioedema, urticaria, contact dermatitis, and rash. If such reactions occur, the spray should be discontinued. The label also warns about potential worsening of existing infections, including tuberculosis and fungal, bacterial, viral, or parasitic disease, as well as ocular herpes simplex. In susceptible patients, chickenpox or measles can follow a more serious course.
These precautions reflect the immunologic cost of corticosteroid exposure. Local anti-inflammatory benefit does not cancel systemic immune effects, especially when patients already carry an active infection or have limited host defenses. The risk is not unique to oral or injected steroids; it remains relevant when an inhaled or intranasal corticosteroid is used in a susceptible host.
Strong CYP3A4 Inhibitors Can Turn a Local Drug Into a Systemic Problem
The interaction section is brief but clinically important. Strong cytochrome P450 3A4 inhibitors such as ritonavir and ketoconazole are not recommended with fluticasone propionate nasal spray because they may increase the risk of systemic corticosteroid effects. The label’s warning aligns with the known dependence of fluticasone clearance on CYP3A4 metabolism.
When metabolism slows, corticosteroid exposure can rise enough to create problems that do not belong in a nasal-only treatment plan: hypercorticism, adrenal suppression, and broader systemic steroid effects. The label explicitly warns that these changes may occur with very high dosages or even at regular dosing in susceptible individuals, and it advises slow discontinuation if such changes develop.
Hepatic impairment also deserves attention. Patients with liver dysfunction should be monitored for signs of increased drug exposure, again reinforcing that hepatic metabolism is central to this product’s safety profile.
Growth Monitoring Remains Mandatory in Children
For pediatric patients, the label requires monitoring of growth. That instruction is especially relevant because the drug is approved for children aged 4 years and older, a group in which prolonged corticosteroid exposure raises concern about linear growth effects. The label does not provide a separate growth rate estimate here; it simply directs clinicians to watch for change and treat growth surveillance as part of routine care.
The adverse-reaction profile in clinical trials is otherwise consistent with a nasal corticosteroid: headache, pharyngitis, epistaxis, nasal burning or irritation, nausea or vomiting, asthma symptoms, and cough each appear among the most common events, defined in the label as occurring in more than 3% of patients.
A Familiar Drug, with Clear Guardrails Around Its Use
The prescribing information for fluticasone propionate nasal spray does not expand the drug’s indication, but it sharpens the boundaries around safe use. Adults and children 4 years and older can receive it for perennial nonallergic rhinitis, yet the label repeatedly emphasizes local inspection, eye vigilance, infection awareness, and drug-interaction screening.
For clinicians, the key bedside issue is matching a common intranasal therapy to the patient in front of them. Prior nasal trauma, long-term use, ocular symptoms, strong CYP3A4 inhibitors, pediatric growth concerns, and hepatic impairment all shift the risk-benefit balance. The label closes those gaps with direct warnings rather than leaving them to assumption, and the safety profile it describes depends as much on patient selection and follow-up as on the spray itself.